European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update
Autor: | Simona Sacco, Faisal Mohammad Amin, Messoud Ashina, Lars Bendtsen, Christina I. Deligianni, Raquel Gil-Gouveia, Zaza Katsarava, Antoinette MaassenVanDenBrink, Paolo Martelletti, Dimos-Dimitrios Mitsikostas, Raffaele Ornello, Uwe Reuter, Margarita Sanchez-del-Rio, Alexandra J. Sinclair, Gisela Terwindt, Derya Uluduz, Jan Versijpt, Christian Lampl |
---|---|
Přispěvatelé: | Clinical sciences, Neuroprotection & Neuromodulation, Neurology, Veritati - Repositório Institucional da Universidade Católica Portuguesa |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
Headache/drug therapy
Calcitonin Gene-Related Peptide Migraine Disorders Neuroscience(all) neurology Prevention Headache Medizin Migraine Disorders/drug therapy Antibodies Monoclonal Antibodies Monoclonal/therapeutic use Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacology General Medicine Guideline Calcitonin Gene-Related Peptide/metabolism Calcitonin gene-related pathway Anesthesiology and Pain Medicine Calcitonin Gene-Related Peptide Receptor Antagonists Migraine Monoclonal antibodies Humans Neurology (clinical) |
Zdroj: | Journal of Headache and Pain, 23(1). BMC Sacco, S, Amin, F M, Ashina, M, Bendtsen, L, Deligianni, C I, Gil-Gouveia, R, Katsarava, Z, MaassenVanDenBrink, A, Martelletti, P, Mitsikostas, D D, Ornello, R, Reuter, U, Sanchez-del-Rio, M, Sinclair, A J, Terwindt, G, Uluduz, D, Versijpt, J & Lampl, C 2022, ' European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update ', Journal of Headache and Pain, vol. 23, 67 . https://doi.org/10.1186/s10194-022-01431-x |
Popis: | Background A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs) and real-world evidence have expanded the evidence and knowledge for those treatments. Therefore, the EHF panel decided to provide an updated guideline on the use of those treatments. Methods The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed a systematic review and an analysis of the literature, assessed the quality of the available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided. Results We found moderate to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in individuals with episodic and chronic migraine. For several important clinical questions, we found not enough evidence to provide evidence-based recommendations and guidance relied on experts’ opinion. Nevertheless, we provided updated suggestions regarding the long-term management of those treatments and their place with respect to the other migraine preventatives. Conclusion Monoclonal antibodies targeting the CGRP pathway are recommended for migraine prevention as they are effective and safe also in the long-term. |
Databáze: | OpenAIRE |
Externí odkaz: |